Clinical trials
Locally Advanced Cervical Cancer clinical trials
Below are recruiting locally advanced cervical cancer clinical trials, each written for real people, not researchers. We’re tracking 407 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05994365Recruiting
Testing anlotinib for advanced thyroid cancer that resists radioactive iodine
This trial tests a targeted therapy pill (anlotinib) for people with advanced thyroid cancer that stopped responding to radioactive iodine. It may slow tumor growth or shrink tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT06163391RecruitingPhase 1
SOT201 for advanced solid tumors
This trial tests a new drug called SOT201 for people with advanced solid cancers that have stopped responding to other treatments. It helps the immune system fight the cancer more effectively.
Houston, TexasAges 18 years+ - NCT06256224Recruiting
Toripalimab with standard chemoradiation for advanced cervical cancer
This trial combines the immunotherapy drug toripalimab with standard chemoradiation to treat newly diagnosed advanced cervical cancer. It aims to see if adding toripalimab improves outcomes for patients whose cancer has not spread to distant organs.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06349980RecruitingPhase 2
Study of three drugs for liver cancer not yet treated
This trial is testing a combination of three drugs (HLX10, HLX04, and HLX53) to find the best dose and see if they help people with advanced liver cancer who have not had systemic treatment before. The goal is to shrink tumors and improve survival.
ShanghaiAges 18 years+ - NCT06742892RecruitingPhase 2
Study of HLX43 for advanced liver cancer after standard treatment fails
This trial tests a new drug, HLX43, for people with advanced liver cancer (HCC) that has worsened or caused intolerable side effects after standard treatments like immunotherapy or targeted therapy. The goal is to see if HLX43 can help when other options have stopped working.
Hunan, HunanAges 18–75 - NCT06878222RecruitingPhase 2
Testing an immunotherapy combo before surgery for cervical cancer
This trial tests whether combining two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy (paclitaxel and cisplatin) before surgery can help shrink cervical cancer. It is for people with certain stages of cervical cancer who are candidates for surgery, including those who want to preserve their fertility.
ShanghaiAges 18–75 - NCT06927986RecruitingPhase 3
Testing SYS6010 vs chemo for advanced EGFR-mutated lung cancer
This trial tests a new drug called SYS6010 compared to standard chemotherapy for people with EGFR-mutated lung cancer that has stopped responding to pill treatments. It may offer a new option if your current EGFR TKI is no longer working.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07293468RecruitingPhase 2/Phase 3
Comparing two treatments for advanced liver cancer
This trial tests two different ways to treat liver cancer that can't be removed with surgery. It compares stereotactic body radiation therapy (targeted high-dose radiation) with selective internal radiation therapy (tiny radioactive beads delivered through a blood vessel), both combined with immunotherapy (medicines that help your immune system fight cancer).
Hong KongAges 18–80 - NCT06540326RecruitingPhase 2
Second-line therapy for advanced colorectal cancer
This trial tests a combination of chemotherapy with either bevacizumab or cetuximab as a second-line treatment for advanced colorectal cancer. It aims to find which option works better for patients whose first treatment failed.
Hangzhou, ZhejiangAges 18–75 - NCT05856383Recruiting
HER2-positive metastatic breast cancer drug combination study
This trial tests whether inetetamab combined with pyrotinib and vinorelbine works better and is safe for adults with HER2-positive advanced breast cancer. You may be considered if standard options have not removed the cancer with surgery and your body can handle chemotherapy and HER2-targeting medicines.
Hangzhou, ZhejiangAges 18 years+ - NCT04752826RecruitingPhase 1/Phase 2
Testing BI-1808 plus Keytruda for advanced cancers
This trial tests a new cancer medicine (BI-1808) either alone or together with Keytruda (pembrolizumab) in people with advanced cancers. It may help by strengthening the immune system’s attack on cancer, especially if standard treatments are no longer working or aren’t suitable.
Duarte, CaliforniaAges 18 years+ - NCT06950086RecruitingPhase 1/Phase 2
TYK-00540 tablets for advanced solid tumors
This trial tests a new tablet, TYK-00540, alone or with another drug, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05451043RecruitingPhase 2
Durvalumab and tremelimumab plus chemotherapy with propranolol
This Phase 2 study tests whether adding propranolol to durvalumab and tremelimumab along with chemotherapy can help control advanced pancreatic cancer, liver cancer, or bile duct cancer. It aims to shrink tumors and help people live longer or feel better when the cancer can’t be cured with surgery or local treatment.
Edmonton, AlbertaAges 18 years+ - NCT07073755Recruiting
Study of next treatments after targeted therapy resistance for advanced breast cancer
This study looks at what happens when people with advanced breast cancer switch to a new treatment after their cancer becomes resistant to targeted therapies like CDK4/6 inhibitors, PIK3CA inhibitors, or T-DXd. Researchers want to understand which next treatments work best in real life.
Changsha, HunanAges 18 years+ - NCT07165067RecruitingPhase 1
Testing AP601 for advanced solid tumors that have not responded to treatment
This trial tests a new drug called AP601 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective, and it targets CD73 and CD137 pathways to help your immune system fight cancer.
Waratah, New South WalesAges 18 years+ - NCT06196697RecruitingPhase 2
New immunotherapy combo for advanced stomach cancer
This clinical trial is testing a combination of two immunotherapy drugs (AK104 and AK112) plus chemotherapy as the first treatment for advanced stomach or gastroesophageal junction cancer. It aims to see if this combination helps control the cancer better than standard therapy.
HarbinAges 18–75 - NCT06481956Enrolling by invitationPhase 2
T-DM1 plus a CDK4/6 inhibitor (ribociclib) for HER2-positive breast cancer
This clinical trial tests a combination of two targeted therapies for people with HER2-positive breast cancer that has spread or come back. The goal is to see if adding ribociclib to T-DM1 is safe and effective after other treatments have been used.
Hangzhou, ZhejiangAges 18–75 - NCT06603376RecruitingPhase 2
Drug combo for BRAF-mutated advanced colorectal cancer
This trial tests a combination of four drugs (irinotecan liposome, fluorouracil, folinic acid, vermofenib, and cetuximab) as a first treatment for people with advanced colorectal cancer that has a specific BRAF V600E mutation. It aims to see if this combination can shrink tumors or slow their growth.
ShanghaiAges 18–80 - NCT06770452RecruitingPhase 2
HRS-4642 combo for first-line advanced pancreatic cancer
This trial tests a new targeted drug (HRS-4642) combined with nimotuzumab and chemotherapy for people with advanced pancreatic cancer that has a specific gene change called KRAS G12D. It's for those who haven't had treatment for advanced disease yet.
Hangzhou, ZhejiangAges 18–75 - NCT07309185RecruitingPhase 2
Adebrelimab, famitinib, and irinotecan for advanced stomach cancer
This trial tests a combination of three drugs (adebrelimab, famitinib, and irinotecan) for people with advanced stomach or gastroesophageal junction cancer that got worse after first-line treatment. It may offer a new option if you have already tried standard therapy.
Jinan, ShandongAges 18–75 - NCT04389281RecruitingPhase 1
X-ray light-activated therapy for hard-to-treat skin tumors
This early-phase study tests an X-ray–activated medicine that is delivered directly into selected tumors to help control cancer that has not responded to standard treatments. If the injected area can be treated safely, it may shrink or slow the tumor and improve local control.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06689540RecruitingPhase 1
MTS105 for advanced liver cancer with GPC3
This trial tests a new treatment called MTS105 for people with advanced liver cancer (HCC) that has not responded to standard therapies. It targets a protein called GPC3 found on some liver cancer cells, aiming to stop the cancer from growing.
BeijingAges 18 years+ - NCT07213570RecruitingPhase 2
Second-line regorafenib for advanced RAS-mutant colorectal cancer
This trial tests regorafenib as a second-line treatment for people with advanced colorectal cancer that has a RAS mutation. It aims to see if this targeted therapy can help when the first treatment stopped working.
Naples, ItalyAges 18 years+ - NCT06326502RecruitingPhase 1
A study of ETN101 for advanced liver cancer
This trial tests an experimental oral drug (ETN101) for adults with advanced liver cancer (hepatocellular carcinoma) that has gotten worse after standard treatments or can't be treated with standard therapy. It aims to see if the drug is safe and effective.
SeoulAges 19–65
Hear when a new Locally Advanced Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced cervical cancer?
- Yes. Clin2 currently lists 407 recruiting locally advanced cervical cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced cervical cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced cervical cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Rectal Cancer
- Locally Advanced Breast Cancer
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Locally Advanced Pancreatic Cancer
- Locally Advanced Gastric Cancer
- Locally Advanced Cervical Carcinoma
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.